Ardelyx (ARDX)
(Delayed Data from NSDQ)
$6.45 USD
-0.29 (-4.30%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $6.45 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Ardelyx, Inc. [ARDX]
Reports for Purchase
Showing records 61 - 80 ( 172 total )
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Tenapanor AdCom: Where Have We Seen This Before? FDA About-Face?
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
FDA Briefing Documents Still Keep This One Tough To Call
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Tough To Call Is Probably An Understatement - ARDX Advancing Towards AdCom
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
3Q22 Commercial Biotech Preview: Regulatory Catalysts Likely The Main Event
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Ibsrela Launch Under The Spotlight In 2Q22 Report
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Xphozah (tenapanor) AdCom Scheduled But Long Road Remains In Place
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Tenapanor Two-Step: Regulatory Reassessment and Commercial Launch
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Ups And Downs - FDA To Hold Tenapanor AdCom, While RDX013 Needs More Work
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Moving Closer Towards An Ibsrela Launch - 4Q21 Highlights
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Tenapanor Appeal Denied; ARDX To Appeal the Appeal, But Sights Set on IBS-C
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Sounds Like a Shift? That''s Because It Is - Ibsrela Launch in IBS
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Still Struggling To Find Common Ground With FDA, Workforce Reduction Commences
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Company: Ardelyx, Inc.
Industry: Medical - Drugs
An Uneventful 2Q21 Report As We Look Towards FDA Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L